X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (60582) 60582
Book Chapter (723) 723
Newspaper Article (458) 458
Newsletter (145) 145
Transcript (13) 13
Book / eBook (12) 12
Magazine Article (12) 12
Conference Proceeding (7) 7
Dissertation (7) 7
Web Resource (4) 4
Reference (3) 3
Book Review (2) 2
Government Document (2) 2
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (51835) 51835
life sciences & biomedicine (46239) 46239
humans (36434) 36434
animals (24390) 24390
proteins (17385) 17385
male (16509) 16509
female (14345) 14345
oncology (13922) 13922
kinases (12072) 12072
mice (10665) 10665
cancer (9779) 9779
apoptosis (9757) 9757
gene expression (8607) 8607
signal transduction (8462) 8462
cell biology (8240) 8240
research (8177) 8177
middle aged (7986) 7986
analysis (6738) 6738
aged (6614) 6614
biochemistry & molecular biology (6553) 6553
health aspects (6249) 6249
adult (6220) 6220
care and treatment (6092) 6092
pharmacology & pharmacy (5991) 5991
research article (5860) 5860
medicine (5788) 5788
phosphorylation (5772) 5772
rodents (5686) 5686
rats (5555) 5555
science & technology - other topics (5542) 5542
tumors (5521) 5521
mutation (5513) 5513
inflammation (5425) 5425
multidisciplinary sciences (5349) 5349
protein kinase inhibitors - therapeutic use (5146) 5146
physiological aspects (4799) 4799
cell line, tumor (4666) 4666
antineoplastic agents - therapeutic use (4546) 4546
signal transduction - drug effects (4535) 4535
genetic aspects (4515) 4515
treatment outcome (4374) 4374
science (4368) 4368
chemotherapy (4341) 4341
studies (4164) 4164
review (4159) 4159
biology (4070) 4070
cancer therapies (3992) 3992
protein kinase inhibitors - adverse effects (3946) 3946
metastasis (3864) 3864
medicine, research & experimental (3681) 3681
research & experimental medicine (3679) 3679
disease models, animal (3630) 3630
apoptosis - drug effects (3622) 3622
cell cycle (3605) 3605
patients (3596) 3596
oxidative stress (3535) 3535
hematology (3498) 3498
cytokines (3451) 3451
clinical trials (3439) 3439
physiology (3397) 3397
medicine & public health (3379) 3379
neurosciences (3375) 3375
cells, cultured (3374) 3374
metabolism (3320) 3320
risk factors (3228) 3228
development and progression (3206) 3206
medical research (3192) 3192
immunology (3173) 3173
neurosciences & neurology (3164) 3164
drug therapy (3147) 3147
antineoplastic agents - adverse effects (3055) 3055
mice, inbred c57bl (3048) 3048
enzymes (3018) 3018
prognosis (3011) 3011
cell proliferation (3003) 3003
genes (2995) 2995
abridged index medicus (2982) 2982
tyrosine (2893) 2893
breast cancer (2888) 2888
antineoplastic agents - pharmacology (2723) 2723
aged, 80 and over (2702) 2702
stem cells (2600) 2600
cell line (2591) 2591
protein kinase inhibitors - pharmacology (2546) 2546
deoxyribonucleic acid--dna (2530) 2530
diabetes (2519) 2519
dose-response relationship, drug (2491) 2491
biochemistry (2465) 2465
medical prognosis (2443) 2443
rats, sprague-dawley (2407) 2407
biomarkers (2395) 2395
cell proliferation - drug effects (2392) 2392
pharmacology (2380) 2380
lipids (2373) 2373
chemistry (2365) 2365
toxicity (2347) 2347
cell growth (2320) 2320
immunohistochemistry (2275) 2275
leukemia (2241) 2241
life sciences (2235) 2235
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (61659) 61659
Japanese (176) 176
German (113) 113
French (112) 112
Chinese (87) 87
Spanish (42) 42
Portuguese (26) 26
Norwegian (20) 20
Dutch (16) 16
Russian (14) 14
Italian (10) 10
Czech (7) 7
Hungarian (7) 7
Turkish (6) 6
Danish (5) 5
Polish (5) 5
Swedish (4) 4
Croatian (2) 2
Finnish (2) 2
Korean (2) 2
Arabic (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK -positive non... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Cancer discovery, ISSN 2159-8290, 04/2017, Volume 7, Issue 4, pp. 400 - 409
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Benzamides - pharmacokinetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Receptor, trkA - antagonists & inhibitors | Male | Receptor, trkB - genetics | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Mammary Analogue Secretory Carcinoma - genetics | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Membrane Glycoproteins - antagonists & inhibitors | Receptor, trkC - genetics | Anaplastic Lymphoma Kinase | Melanoma - genetics | Colorectal Neoplasms - drug therapy | Receptor, trkB - antagonists & inhibitors | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Benzamides - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Crizotinib | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Pyridines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Receptor, trkC - antagonists & inhibitors | Melanoma - pathology | Mammary Analogue Secretory Carcinoma - drug therapy | Membrane Glycoproteins - genetics | Protein Kinase Inhibitors - administration & dosage | Sequestosome-1 Protein - genetics | Pyrazoles - administration & dosage | Indazoles - pharmacokinetics | Receptor Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - genetics | Melanoma - drug therapy | Adolescent | Receptor, trkA - genetics | Oncogene Proteins, Fusion - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Indazoles - adverse effects | Colorectal Neoplasms - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 04/2017, Volume 76, Issue 4, pp. 745 - 753.e19
Background Janus kinase (JAK) inhibitors are emerging as a promising new treatment modality for many inflammatory conditions... 
Dermatology | dermatology | psoriasis | baricitinib | vitiligo | atopic dermatitis | ruxolitinib | alopecia areata | JAK inhibitors | graft versus host disease | tofacitinib | Life Sciences & Biomedicine | Science & Technology | Pyrazoles - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Antineoplastic Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Drug Eruptions - etiology | Psoriasis - drug therapy | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Randomized Controlled Trials as Topic | Janus Kinases - antagonists & inhibitors | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Mutual fund industry | Lupus | Psoriasis | Dermatologic agents | Arthritis | Non-Hodgkin's lymphomas | T cells | Rheumatoid factor | Atopic dermatitis | Analysis | Formulae, receipts, prescriptions | Respiratory tract diseases | Skin | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2015, Volume 372, Issue 1, pp. 30 - 39
..., in patients with metastatic melanoma with BRAF V600E or V600K mutations. 1 , 2 However, acquired resistance to BRAF inhibitors frequently develops through reactivation of the mitogen-activated protein kinase (MAPK... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2007, Volume 370, Issue 9604, pp. 2011 - 2019
Journal Article